Below you will find a list of the most recent publications from the Neubauer lab (2020 – present). For a complete list of publications please follow this link.
2025
Multi-omics Profiling of T-cell Leukemia and Lymphoma Enables Targeted Therapeutic Discovery. Ianevski A, Nader K, Nguyen J, Sorger H, Timonen S, Julia E, Pölöske D, Spirk K, Wagner C, Jungherz D, Nakano M, Kadambat Nair S, Ianevski P, Kankainen M, Dias D, Cichońska A, Pemovska T, Pirker C, Berger W, Braun T, Moriggl R, Bachy E, Mustjoki S, Herling M, Neubauer HA, Haibe-Kains B, Aittokallio T. Cancer Res. 2025 Oct 30. doi: 10.1158/0008-5472.CAN-25-0881
Thyroid hormone receptor beta signaling is a targetable driver of prostate cancer growth. Fesiuk A, Pölöske D, de Araujo ED, Frere GA, Wright TB, Tin G, Raouf YS, Olaoye OO, Park JS, Blavet N, Tichý B, Schlederer M, Högler S, Wolf M, Philippe C, Aksoy O, Varady A, Mata AM, Varenicja M, Szabó B, Weiss T, Wasinger G, Redmer T, Neubauer HA, Susani M, Spielvogel CP, Ning J, Dahlhoff M, Schepelmann M, Kennedy R, Moriggl R, Brown G, Persson J, Gerner C, Bystry V, Hollóczki O, Heery DM, Gunning PT, Merkel O, Hantusch B, Kenner L. Mol Cancer. 2025 Oct 14;24(1): 256. doi: 10.1186/s12943-025-02451-2
Dual STAT3/STAT5 inhibition as a novel treatment strategy in T-prolymphocytic leukemia. Dechow A, Timonen S, Ianevski A, Jiang Q, Wahnschaffe L, Peng Y, Jungherz D, Becker K, Neubauer HA, Schönefeldt S, de Araujo E, Gunning P, Fleck R, Schrader A, Hallek M, Pflug N, Moriggl R, Aittokallio T, Mustjoki S, Braun T, Herling M. Leukemia. 2025 Jun;39(6): 1435-1448. doi: 10.1038/s41375-025-02577-8
2024
Dual specific STAT3/5 degraders effectively block acute myeloid leukemia and natural killer/T cell lymphoma. Pölöske D, Sorger H, Schönbichler A, de Araujo ED, Neubauer HA, Orlova A, Timonen SH, Abdallah DI, Ianevski A, Kuusanmäki H, Surbek M, Heyes E, Eder T, Wagner C, Suske T, Metzelder ML, Bergmann M, Dahlhoff M, Grebien F, Fleck R, Pirker C, Berger W, Hadzijusufovic E, Sperr WR, Kenner L, Valent P, Aittokallio T, Herling M, Mustjoki S, Gunning PT, Moriggl R. Hemasphere. 2024 Nov 28;8(12): e70001. doi: 10.1002/hem3.70001
Cell-autonomous IL6ST activation suppresses prostate cancer development via STAT3/ARF/p53-driven senescence and confers an immune-active tumor microenvironment. Sternberg C, Raigel M, Limberger T, Trachtová K, Schlederer M, Lindner D, Kodajova P, Yang J, Ziegler R, Kalla J, Stoiber S, Dey S, Zwolanek D, Neubauer HA, Oberhuber M, Redmer T, Hejret V, Tichy B, Tomberger M, Harbusch NS, Pencik J, Tangermann S, Bystry V, Persson JL, Egger G, Pospisilova S, Eferl R, Wolf P, Sternberg F, Högler S, Lagger S, Rose-John S, Kenner L. Mol Cancer. 2024 Oct 31;23(1): 245. doi: 10.1186/s12943-024-02114-8
Boosting the anti-tumor activity of natural killer cells by caripe 8 – A Carapichea ipecacuanha isolated cyclotide. List J, Gattringer J, Huszarek S, Marinovic S, Neubauer HA, Kudweis P, Putz EM, Hellinger R, Gotthardt D. Biomed Pharmacother. 2024 Aug;177: 117057. doi: 10.1016/j.biopha.2024.117057
Optimizing drug combinations for T-PLL: restoring DNA damage and P53-mediated apoptotic responses. von Jan J, Timonen S, Braun T, Jiang Q, Ianevski A, Peng Y, McConnell K, Sindaco P, Müller TA, Pützer S, Klepzig H, Jungherz D, Dechow A, Wahnschaffe L, Giri AK, Kankainen M, Kuusanmäki H, Neubauer HA, Moriggl R, Mazzeo P, Schmidt N, Koch R, Hallek M, Chebel A, Armisen D, Genestier L, Bachy E, Mishra A, Schrader A, Aittokallio T, Mustjoki S, Herling M. Blood. 2024 Oct 10;144(15): 1595-1610. doi: 10.1182/blood.2023022884
JUN mediates the senescence associated secretory phenotype and immune cell recruitment to prevent prostate cancer progression. Redmer T, Raigel M, Sternberg C, Ziegler R, Probst C, Lindner D, Aufinger A, Limberger T, Trachtova K, Kodajova P, Högler S, Schlederer M, Stoiber S, Oberhuber M, Bolis M, Neubauer HA, Miranda S, Tomberger M, Harbusch NS, Garces de Los Fayos Alonso I, Sternberg F, Moriggl R, Theurillat JP, Tichy B, Bystry V, Persson JL, Mathas S, Aberger F, Strobl B, Pospisilova S, Merkel O, Egger G, Lagger S, Kenner L. Mol Cancer. 2024 May 29;23(1): 114. doi: 10.1186/s12943-024-02022-x
JAK-STAT signaling maintains homeostasis in T cells and macrophages. Fortelny N, Farlik M, Fife V, Gorki AD, Lassnig C, Maurer B, Meissl K, Dolezal M, Boccuni L, Ravi Sundar Jose Geetha A, Akagha MJ, Karjalainen A, Shoebridge S, Farhat A, Mann U, Jain R, Tikoo S, Zila N, Esser-Skala W, Krausgruber T, Sitnik K, Penz T, Hladik A, Suske T, Zahalka S, Senekowitsch M, Barreca D, Halbritter F, Macho-Maschler S, Weninger W, Neubauer HA, Moriggl R, Knapp S, Sexl V, Strobl B, Decker T, Müller M, Bock C. Nat Immunol. 2024 May;25(5): 847-859. doi: 10.1038/s41590-024-01804-1
Hyperactive STAT5 hijacks T cell receptor signaling and drives immature T cell acute lymphoblastic leukemia. Suske T, Sorger H, Manhart G, Ruge F, Prutsch N, Zimmerman MW, Eder T, Abdallah DI, Maurer B, Wagner C, Schönefeldt S, Spirk K, Pichler A, Pemovska T, Schweicker C, Pölöske D, Hubanic E, Jungherz D, Müller TA, Aung MMK, Orlova A, Pham HTT, Zimmel K, Krausgruber T, Bock C, Müller M, Dahlhoff M, Boersma A, Rülicke T, Fleck R, de Araujo ED, Gunning PT, Aittokallio T, Mustjoki S, Sanda T, Hartmann S, Grebien F, Hoermann G, Haferlach T, Staber PB, Neubauer HA, Look AT, Herling M, Moriggl R. J Clin Invest. 2024 Apr 15;134(8): e168536. doi: 10.1172/JCI168536
2023
STAT3/LKB1 controls metastatic prostate cancer by regulating mTORC1/CREB pathway. Pencik J, Philippe C, Schlederer M, Atas E, Pecoraro M, Grund-Gröschke S, Li WJ, Tracz A, Heidegger I, Lagger S, Trachtová K, Oberhuber M, Heitzer E, Aksoy O, Neubauer HA, Wingelhofer B, Orlova A, Witzeneder N, Dillinger T, Redl E, Greiner G, D’Andrea D, Östman JR, Tangermann S, Hermanova I, Schäfer G, Sternberg F, Pohl EE, Sternberg C, Varady A, Horvath J, Stoiber D, Malcolm TI, Turner SD, Parkes EE, Hantusch B, Egger G, Rose-John S, Poli V, Jain S, Armstrong CWD, Hoermann G, Goffin V, Aberger F, Moriggl R, Carracedo A, McKinney C, Kennedy RD, Klocker H, Speicher MR, Tang DG, Moazzami AA, Heery DM, Hacker M, Kenner L. Mol Cancer. 2023 Aug 12;22(1): 133. doi: 10.1186/s12943-023-01825-8
2022
High Efficacy and Drug Synergy of HDAC6-Selective Inhibitor NN-429 in Natural Killer (NK)/T-Cell Lymphoma. Garcha HK, Nawar N, Sorger H, Erdogan F, Aung MMK, Sedighi A, Manaswiyoungkul P, Seo HS, Schönefeldt S, Pölöske D, Dhe-Paganon S, Neubauer HA, Mustjoki SM, Herling M, de Araujo ED, Moriggl R, Gunning PT. Pharmaceuticals (Basel). 2022 Oct 26;15(11): 1321. doi: 10.3390/ph15111321
Blocking STAT3/5 through direct or upstream kinase targeting in leukemic cutaneous T-cell lymphoma. Sorger H, Dey S, Vieyra-Garcia PA, Pölöske D, Teufelberger AR, de Araujo ED, Sedighi A, Graf R, Spiegl B, Lazzeri I, Braun T, Garces de Los Fayos Alonso I, Schlederer M, Timelthaler G, Kodajova P, Pirker C, Surbek M, Machtinger M, Graier T, Perchthaler I, Pan Y, Fink-Puches R, Cerroni L, Ober J, Otte M, Albrecht JD, Tin G, Abdeldayem A, Manaswiyoungkul P, Olaoye OO, Metzelder ML, Orlova A, Berger W, Wobser M, Nicolay JP, André F, Nguyen VA, Neubauer HA, Fleck R, Merkel O, Herling M, Heitzer E, Gunning PT, Kenner L, Moriggl R, Wolf P. EMBO Mol Med. 2022 Dec 7;14(12): e15200. doi: 10.15252/emmm.202115200
PDGFRβ promotes oncogenic progression via STAT3/STAT5 hyperactivation in anaplastic large cell lymphoma. Garces de Los Fayos Alonso I, Zujo L, Wiest I, Kodajova P, Timelthaler G, Edtmayer S, Zrimšek M, Kollmann S, Giordano C, Kothmayer M, Neubauer HA, Dey S, Schlederer M, Schmalzbauer BS, Limberger T, Probst C, Pusch O, Högler S, Tangermann S, Merkel O, Schiefer AI, Kornauth C, Prutsch N, Zimmerman M, Abraham B, Anagnostopoulos J, Quintanilla-Martinez L, Mathas S, Wolf P, Stoiber D, Staber PB, Egger G, Klapper W, Woessmann W, Look TA, Gunning P, Turner SD, Moriggl R, Lagger S, Kenner L. Mol Cancer. 2022 Aug 31;21(1): 172. doi: 10.1186/s12943-022-01640
2021
The Diverse Roles of γδ T Cells in Cancer: From Rapid Immunity to Aggressive Lymphoma. Schönefeldt S, Wais T, Herling M, Mustjoki S, Bekiaris V, Moriggl R, Neubauer HA. Cancers (Basel). 2021 Dec 9;13(24): 6212. doi: 10.3390/cancers13246212
Proteomic Analysis Identifies NDUFS1 and ATP5O as Novel Markers for Survival Outcome in Prostate Cancer. Wiebringhaus R, Pecoraro M, Neubauer HA, Trachtová K, Trimmel B, Wieselberg M, Pencik J, Egger G, Krall C, Moriggl R, Mann M, Hantusch B, Kenner L. Cancers (Basel). 2021 Nov 30;13(23): 6036. doi: 10.3390/cancers13236036
A Recurrent STAT5BN642H Driver Mutation in Feline Alimentary T Cell Lymphoma. Kieslinger M, Swoboda A, Kramer N, Freund P, Pratscher B, Neubauer HA, Steinborn R, Wolfesberger B, Fuchs-Baumgartinger A, Moriggl R, Burgener IA. Cancers (Basel). 2021 Oct 19;13(20): 5238. doi: 10.3390/cancers13205238
Development of HDAC Inhibitors Exhibiting Therapeutic Potential in T-Cell Prolymphocytic Leukemia. Toutah K, Nawar N, Timonen S, Sorger H, Raouf YS, Bukhari S, von Jan J, Ianevski A, Gawel JM, Olaoye OO, Geletu M, Abdeldayem A, Israelian J, Radu TB, Sedighi A, Bhatti MN, Hassan MM, Manaswiyoungkul P, Shouksmith AE, Neubauer HA, de Araujo ED, Aittokallio T, Krämer OH, Moriggl R, Mustjoki S, Herling M, Gunning PT. J Med Chem. 2021 Jun 24;64(12): 8486-8509. doi: 10.1021/acs.jmedchem.1c00420
Opioids drive breast cancer metastasis through the δ-opioid receptor and oncogenic STAT3. Tripolt S, Neubauer HA, Knab VM, Elmer DP, Aberger F, Moriggl R, Fux DA. Neoplasia. 2021 Feb;23(2): 270-279. doi: 10.1016/j.neo.2020.12.011
Thyroid and androgen receptor signaling are antagonized by μ-Crystallin in prostate cancer. Aksoy O, Pencik J, Hartenbach M, Moazzami AA, Schlederer M, Balber T, Varady A, Philippe C, Baltzer PA, Mazumder B, Whitchurch JB, Roberts CJ, Haitel A, Herac M, Susani M, Mitterhauser M, Marculescu R, Stangl-Kremser J, Hassler MR, Kramer G, Shariat SF, Turner SD, Tichy B, Oppelt J, Pospisilova S, Hartenbach S, Tangermann S, Egger G, Neubauer HA, Moriggl R, Culig Z, Greiner G, Hoermann G, Hacker M, Heery DM, Merkel O, Kenner L. Int J Cancer. 2021 Feb 1;148(3): 731-747. doi: 10.1002/ijc.33332
2020
STAT5 is Expressed in CD34+/CD38– Stem Cells and Serves as a Potential Molecular Target in Ph-Negative Myeloproliferative Neoplasms. Hadzijusufovic E, Keller A, Berger D, Greiner G, Wingelhofer B, Witzeneder N, Ivanov D, Pecnard E, Nivarthi H, Schur FKM, Filik Y, Kornauth C, Neubauer HA, Müllauer L, Tin G, Park J, de Araujo ED, Gunning PT, Hoermann G, Gouilleux F, Kralovics R, Moriggl R, Valent P. Cancers (Basel). 2020 Apr 21;12(4). pii: E1021. doi: 10.3390/cancers12041021
The neonatal microenvironment programs innate γδ T cells through the transcription factor STAT5. Kadekar D, Agerholm R, Rizk J, Neubauer HA, Suske T, Maurer B, Viñals MT, Comelli EM, Taibi A, Moriggl R, Bekiaris V.
J Clin Invest. 2020 Apr 13. pii: 131241. doi: 10.1172/JCI131241
Pharmacological Inhibition of Oncogenic STAT3 and STAT5 Signaling in Hematopoietic Cancers. Brachet-Botineau M, Polomski M, Neubauer HA, Juen L, Hédou D, Viaud-Massuard MC, Prié G, Gouilleux F. Cancers (Basel). 2020 Jan 18;12(1). pii: E240. doi: 10.3390/cancers12010240
The Neubauer Lab 